“According to a new report published by Introspective Market Research, Proliferative Diabetic Retinopathy Market by Treatment Type, Mode of Administration, and End-User, The Global Proliferative Diabetic Retinopathy Market Size Was Valued at USD 9.61 Billion in 2024 and is Projected to Reach USD 19.23 Billion by 2035, Growing at a CAGR of 6.51%.”

Proliferative Diabetic Retinopathy (PDR) represents the advanced stage of diabetic eye disease, a severe microvascular complication of both type 1 and type 2 diabetes. PDR is characterized by the growth of abnormal new blood vessels (neovascularization) on the surface of the retina and into the vitreous gel, often leading to serious vision-threatening complications such as vitreous hemorrhage and tractional retinal detachment. It stands as a leading cause of irreversible blindness among the working-age population globally.

The market for Proliferative Diabetic Retinopathy treatment comprises pharmaceutical interventions like Anti-VEGF (Vascular Endothelial Growth Factor) agents, intraocular steroids, and surgical procedures such as laser photocoagulation and vitrectomy. Anti-VEGF therapy has revolutionized care, offering a less invasive alternative to traditional laser surgery by directly inhibiting the growth of abnormal vessels and reducing associated fluid leakage. Its advantage lies in improving vision in many patients, whereas traditional treatments often aim primarily to preserve existing vision. Major industries driving this market include the biopharmaceutical sector, medical device manufacturers, and specialized eye care providers (ophthalmology clinics and hospitals).

Market Segmentation:

The Proliferative Diabetic Retinopathy Market is segmented into Treatment Type, Mode of Administration, and End-User. By Treatment Type, the market is categorized into (Anti-VEGF Therapy, Laser Surgery, Vitrectomy, Intraocular Steroids). By Mode of Administration, the market is categorized into (Intravitreal Injections, Sub-retinal, Topical & Periocular). By End-User, the market is categorized into (Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers).

Growth Driver:

The primary growth driver for the Proliferative Diabetic Retinopathy (PDR) market is the escalating global prevalence of diabetes and associated risk factors like obesity and sedentary lifestyles. Diabetes is reaching epidemic proportions worldwide, and prolonged elevated blood sugar levels are the direct precursor to PDR. Given that a significant percentage of both Type 1 and Type 2 diabetics develop some form of retinopathy over time, the rapidly expanding global diabetic population directly increases the pool of patients at risk for PDR. This demographic shift is creating a consistent, long-term demand for effective diagnostic screening programs and advanced therapeutic interventions to manage the sight-threatening complications of the disease, thereby propelling market expansion.

Market Opportunity:

A significant market opportunity lies in the development and integration of advanced diagnostic technologies, particularly those utilizing Artificial Intelligence (AI) and telemedicine platforms. Early diagnosis is critical for effective PDR management, yet many low- and middle-income countries lack adequate access to trained eye-care professionals. AI-enabled retinal screening systems and portable imaging devices can autonomously detect and grade diabetic retinopathy lesions, even in remote settings. Integrating these systems with telemedicine platforms allows ophthalmologists to remotely monitor and diagnose patients, significantly improving compliance with annual eye exams and facilitating timely referral for treatment, which is poised to unlock substantial market growth in underserved populations.

Detailed Segmentation:

Proliferative Diabetic Retinopathy Market, Segmentation

The Proliferative Diabetic Retinopathy Market is segmented on the basis of Treatment Type, Mode of Administration, and End-User.

Treatment Type

The Treatment Type segment is further classified into Anti-VEGF Therapy, Laser Surgery, Vitrectomy, and Intraocular Steroids. Among these, the Anti-VEGF Therapy sub-segment accounted for the highest market share in 2024. Anti-VEGF agents, such as Aflibercept and Ranibizumab, have become the standard first-line treatment for PDR and associated complications like Diabetic Macular Edema (DME). These drugs are injected directly into the eye (intravitreally) to block Vascular Endothelial Growth Factor, a protein responsible for stimulating the growth of the fragile, abnormal blood vessels characteristic of PDR. Their high efficacy in reducing vessel leakage, halting neovascularization, and improving vision, coupled with relatively quick administration, drives their widespread adoption and dominant market share, often replacing laser therapy as the initial intervention.

Mode of Administration

The Mode of Administration segment is further classified into Intravitreal Injections, Sub-retinal, and Topical & Periocular. Among these, the Intravitreal Injections sub-segment accounted for the highest market share in 2024. This method involves injecting the drug, typically an Anti-VEGF agent or a steroid, directly into the vitreous cavity of the eye. The intravitreal route ensures that the drug reaches the retina and macula at the therapeutic concentration necessary to effectively suppress neovascularization and edema, with minimal systemic exposure. Despite requiring repeated clinic visits, its proven biological efficacy and the dominance of Anti-VEGF agents as the primary therapeutic class make it the most prevalent and commercially significant mode of delivery in the PDR market.

Some of The Leading/Active Market Players Are-

·         Bayer AG (Germany)

·         Novartis AG (Switzerland)

·         Regeneron Pharmaceuticals, Inc. (U.S.)

·         F. Hoffmann-La Roche Ltd. / Genentech, Inc. (Switzerland/U.S.)

·         AbbVie Inc. (U.S.)

·         Bausch Health Companies Inc. (Canada)

·         Santen Pharmaceutical Co., Ltd. (Japan)

·         Alimera Sciences, Inc. (U.S.)

·         Oxurion NV (Belgium)

·         Kowa Company, Ltd. (Japan)

·         Kodiak Sciences (U.S.)

·         Adverum Biotechnologies (U.S.)

·         Clearside Biomedical (U.S.)

·         Ampio Pharmaceuticals Inc. (U.S.)

and other active players.

Key Industry Developments

FDA Approval of High-Dose Anti-VEGF Therapy

In August 2023, Regeneron Pharmaceuticals, Inc. received FDA approval for its EYLEA HD (aflibercept) Injection, an 8-mg dose, for the treatment of diabetic retinopathy (DR), diabetic macular edema (DME), and wet age-related macular degeneration (wAMD).

This approval of a higher-dose formulation is a significant advance for PDR patients, as it extends the treatment interval for Anti-VEGF therapy to potentially every 16 weeks in some patients. This expansion of dosing frequency is expected to reduce the treatment burden on both patients and eye-care clinics, leading to improved patient compliance and better long-term visual outcomes for individuals managing a chronic condition like Proliferative Diabetic Retinopathy.

Acquisition to Bolster Ophthalmology Pipeline

In July 2024, Merck and Co. Inc., a US-based healthcare company, announced the acquisition of UK-based EyeBio Limited for a total sum of $3 billion to bolster its ophthalmology pipeline.

The strategic acquisition of EyeBio Limited demonstrates a major pharmaceutical company's commitment to advancing novel therapies for sight-threatening retinal diseases. This move is specifically aimed at obtaining expertise and assets focused on developing new treatments for PDR, particularly those targeting abnormal retinal blood vessel growth, indicating a strong future investment and expected growth in the therapeutic segment of the PDR market.

Key Findings of the Study

·         Dominant Segment: Anti-VEGF Therapy holds the largest market share due to its proven efficacy and role as a first-line PDR treatment.

·         Leading Region: North America dominates the global market, driven by high diabetes prevalence and advanced healthcare infrastructure.

·         Key Growth Drivers: The surge in the global diabetic population and the rising rates of associated obesity are the core market drivers.

·         Market Trends: The focus on AI-enabled screening and the development of longer-acting, sustained-release drug implants are key trends to watch.

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the Proliferative Diabetic Retinopathy Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global healthcare industry.

More Info:- https://introspectivemarketresearch.com/reports/proliferative-diabetic-retinopathy-market/

📞 Contact Us Introspective Market Research Pvt. Ltd.

 Phone: +91-91753-37569

 Email: sales@introspectivemarketresearch.com

 Web: www.introspectivemarketresearch.com